Post-approval studies (Phase 4)Study completedNCT00776009
What this trial is testing
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
Who this might be right for
Attention-Deficit/Hyperactivity Disorder (ADHD)
Novartis Pharmaceuticals 165